22-09 ADEPPT

About this trial

ADEPPT is a multicentre, single-arm phase II trial of adagrasib in elderly patients or with poor performance status and KRAS G12C-mutant NSCLC.
This aim of the study is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2).
The trial focuses on providing access and information on novel therapies, in populations commonly excluded from clinical trials. Elderly patients with NSCLC and PS2 are often excluded from clinical trials but constitute >40% of the population with lung cancer. Currently, there are no approved targeted therapy for patients with KRAS G12C-mutant NSCLC available in Ireland.

Patient Profile

1. Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) [Cohort 1]
or
2. Elderly (≥70 years) (ECOG PS=0-1) Cohort 2

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, University Hospital Limerick, and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	22-09 ADEPPT
Number:	22-09
Full Title:	A multicentre, single-arm phase II trial of adagrasib in elderly (≥70 years) patients or with poor performance status and KRAS G12C-mutant NSCLC.

Principal Investigator:	Prof. Jarushka Naidoo
Type:	Collaborative
Sponsor:	ETOP IBCSG
Recruitment Started:	Global: Yes Ireland: Yes

Global Recruitment Target:	68
Ireland Recruitment Target:	Recruitment is competitive